Jordan Cormier, PA
Pulmonary Disease · Idaho Falls, IDNPI 1073027389
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,842 of the $9,248 with a category attached, or 74.0%. 23 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 36.7% of the total.
Across 385 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$3K
- GSK$1K
- Grifols USA, LLC$815
- United Therapeutics Corporation$811
- AstraZeneca$445
- Takeda Pharmaceuticals U.S.A., Inc.$429
- plus $2K from 17 others
What the payments were for
- Travel & lodging$2,32125%
- Food & beverage$6,84274%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 50 | $3,394 |
| GSK | 83 | $1,130 |
| Grifols USA, LLC | 54 | $815 |
| United Therapeutics Corporation | 43 | $811 |
| AstraZeneca | 20 | $445 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $429 |
| Boehringer Ingelheim | 21 | $402 |
| Baxter Healthcare | 15 | $303 |
| Sanofi | 11 | $211 |
| Insmed, Inc. | 7 | $210 |
| Bayer | 10 | $199 |
| Mylan Specialty L.p. | 9 | $187 |
| Harmony Biosciences LLC | 7 | $162 |
| Viatris Specialty LLC | 15 | $152 |
| Regeneron Healthcare Solutions, Inc. | 6 | $107 |
| Philips North America LLC | 4 | $67 |
| Merck | 2 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $47 |
| Fisher & Paykel Healthcare Inc | 2 | $31 |
| Flowonix Medical Incorporated | 1 | $15 |
| Amgen | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,248 in reported general payments places this provider in the 85th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 120 | $80,170 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 154 | $79,160 |
| NucalaMepolizumab | 13 | $47,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $43,238 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,450 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $10,586 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,353 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,413 |
| DuleraMometasone/Formoterol | 11 | $3,611 |
| Roflumilast | 76 | $3,367 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $3,077 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $2,925 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,694 |
| Theophylline ErTheophylline Anhydrous | 28 | $1,426 |
| Ipratropium Bromide | 29 | $920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Anoro Ellipta | $1,130 | $97,98189 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $402 | $92,610172 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $445 | $84,584131 claims |
| MerckDulera | $53 | $3,61111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Idaho Falls
- Allen SalemIdaho Falls$44K
- Todd HoopmanCoeur D Alene$76K
- Mark RasmusBoise$44K
- Shawn FrenchTwin Falls$26K
- Karen MillerMeridian$12K
- Wesley PidcockNampa$12K
- Norman EastBoise$11K
- Oleg KouskovMeridian$8K
- Derek LindermanBoise$7K
- Gregory BallTwin Falls$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.